General Information of Drug Combination (ID: DC73DIS)

Drug Combination Name
BIO-300 DFN-15
Indication
Disease Entry Status REF
Chronic myelogenous leukemia Investigative [1]
Component Drugs BIO-300   DMJ7NVI DFN-15   DM3BF9B
N.A. N.A.
High-throughput Screening Result Testing Cell Line: K-562
Zero Interaction Potency (ZIP) Score: 6.77
Bliss Independence Score: 6.16
Loewe Additivity Score: 5.25
LHighest Single Agent (HSA) Score: 8.38

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Lung adenocarcinoma DC2TBK7 MDA-MB-231 Investigative [5]
Prostate carcinoma DCJHVZN PC-3 Investigative [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.